Spectrum Pharmaceuticals, Inc., a major biopharmaceutical player with a primary focus on oncology drug products, boasts an innovative portfolio of offerings. Some of its key products include ROLVEDON(Eflapegrastim), which is a novel long-acting granulocyte colony-stimulating factor best-suited for chemotherapy-induced neutropenia cases. Poziotinib, on the other hand, is an irreversible tyrosine kinase inhibitor designed for non-small cell lung cancer tumors with various mutations. Notably, Spectrum Pharmaceuticals has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd., and license agreements with Therapyx, Inc. and The University of Texas M.D. Anderson Cancer Center. Spectrum Pharmaceuticals, with roots that go back to 1987, was initially called NeoTherapeutics, Inc. The company decided to change its name to Spectrum Pharmaceuticals, Inc. in December 2002. Furthermore, Spectrum Pharmaceuticals is headquartered in Boston, Massachusetts, and has cemented its place as one of the most promising biopharmaceutical companies in the industry.